| Literature DB >> 32028716 |
Mariangela Marrelli1, Giancarlo Statti1, Filomena Conforti1.
Abstract
Wild foods constitute an essential component of people's diets around the world. According to the Food and Agriculture Organization (FAO), over 100 million people in the EU consume wild foods, while 65 million collect some form of wild food themselves. The Mediterranean basin is a biodiversity hotspot of wild edible species. Nowadays, due to the renewed interest in alimurgic plants and the recent findings on the beneficial role of their phytochemical constituents, these species have been defined as "new functional foods". Research on natural products has recently regained importance with the growing understanding of their biological significance. Botanical food supplements marketed for weight and fat loss in obese subjects will be one of the most important items in marketed nutraceuticals. The aim of this report was to review the phytochemical compounds of Mediterranean wild edible species and their therapeutic potential against obesity and its related disorders. Results on the in vitro and in vivo activity of the most interesting plant extracts and their bioactive components are presented and discussed. The most interesting discoveries on their mechanisms of action are reported as well. Overall, this contribution highlights the importance and beneficial health roles of wild edible species.Entities:
Keywords: alimurgic plant; biodiversity; obesity; phytochemical compound; wild
Mesh:
Substances:
Year: 2020 PMID: 32028716 PMCID: PMC7036856 DOI: 10.3390/molecules25030649
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Current commonly used anti-obesity drugs [22,25].
Extracts from Mediterranean wild edible plants with beneficial effects against obesity and related comorbidities.
| Plant Species | Study | Activity | Class/Bioactive Compounds | References |
|---|---|---|---|---|
| In vitro | α-Amylase-inhibitory activity | [ | ||
| In vitro | Pancreatic lipase inhibition | [ | ||
| In vitro | Pancreatic lipase inhibition | [ | ||
| In vitro | α-Glucosidase-inhibitory activity | 9α-hydroxyparthenolide ( | [ | |
| In vitro | α-Amylase-inhibitory activity | [ | ||
| In vitro | Pancreatic lipase inhibition | [ | ||
| In vitro | α-Glucosidase-inhibitory effects | Chrysophanol ( | [ | |
| In vitro | α-Amylase-inhibitory activity; α-glucosidase-inhibitory activity | Vitexin (21), isovitexin (22), orientin (23) and isoorientin (24) | [ | |
| In vitro | α-Amylase-inhibitory activity | [ | ||
| In vitro | α-Amylase-inhibitory activity; pancreatic-lipase-inhibitory activity | [ | ||
| In vitro | Pancreatic-lipase-inhibitory activity | Rutin ( | [ | |
| In vitro | α-Amylase-inhibitory activity; pancreatic-lipase-inhibitory activity | Rutin ( | [ | |
| In vitro | α-Amylase-inhibitory activity; pancreatic-lipase-inhibitory activity | [ | ||
| In vitro | α-Amylase-inhibitory activity | [ | ||
| In vitro | α-Amylase-inhibitory activity | [ | ||
| In vitro | Pancreatic lipase inhibition | [ | ||
| In vivo | Effectiveness against hyperlipaemia associated or not with hyperglycaemia | [ | ||
| In vitro | Moderate carbohydrate-hydrolyzing enzyme inhibition; | [ | ||
| In vivo | Dose-dependent effect on serum glucose levels in ZDF rats | [ | ||
| In vivo | Rapid blood glucose reduction | [ | ||
| In vitro | α-Amylase-inhibitory activity; pancreatic-lipase-inhibitory activity | [ | ||
| In vitro | α-Amylase inhibitory activity; α-glucosidase-inhibitory activity | [ | ||
| In vivo | Reduction of insulin resistance and glucose tolerance | Naringenin ( | [ | |
| In vitro | Pancreatic lipase inhibition | [ | ||
| In vitro | α-Amylase-inhibitory activity; pancreatic-lipase-inhibitory activity | [ | ||
| In vitro | Pancreatic lipase inhibition | [ | ||
| In vitro | Pancreatic lipase inhibition | [ | ||
| In vitro | α-Amylase-inhibitory activity; pancreatic-lipase-inhibitory activity | [ | ||
| In vitro | α-Amylase-inhibitory activity; pancreatic-lipase-inhibitory activity | [ | ||
| In vitro | α-Amylase-inhibitory activity; pancreatic-lipase-inhibitory activity | [ | ||
| In vitro | Pancreatic lipase inhibition | [ | ||
| In vitro | Pancreatic lipase inhibition | [ | ||
| In vitro | Inhibition of adipogenesis | [ | ||
| In vitro | Pancreatic lipase inhibition | [ | ||
| In vitro | α-Amylase-inhibitory activity; pancreatic-lipase-inhibitory activity | [ | ||
| In vitro | α-Amylase-inhibitory activity | [ | ||
| In vitro | Inhibition of carbohydrate-hydrolyzing enzymes | Nanirutin ( | [ | |
| In vitro | Pancreatic lipase inhibition | [ | ||
| In vitro | Pancreatic lipase inhibition | [ | ||
| In vitro | α-Amylase-inhibitory activity; pancreatic-lipase-inhibitory activity | [ | ||
| In vitro | Pancreatic lipase inhibition | [ | ||
| In vitro | Pancreatic lipase inhibition | [ | ||
| In vitro | Glucosidases (α-, β-), α-amylase, and lipase enzyme inhibition | [ | ||
| In vitro | Pancreatic lipase inhibition | [ | ||
| In vitro | Pancreatic lipase inhibition | [ | ||
| In vitro | α-Amylase-inhibitory activity | [ | ||
| In vitro | Pancreatic lipase inhibition | [ | ||
| In vitro | Pancreatic lipase inhibition | [ | ||
| In vitro | Pancreatic lipase inhibition | [ | ||
| In vitro | Reduced lipid accumulation in macrophages; | [ | ||
| In vivo | Lowering of plasma HbA1c, retinol-binding protein 4, and resistin; | Antocyanins | [ | |
| Reduction of blood glucose levels; | [ | |||
| Lowering of plasma TG, TC, and LDL-C concentrations | [ | |||
| - Reduction in glucose, fasting insulin and insulin resistance | [ |
Figure 2Natural compounds with hypoglycemic properties [26,31,36,40,42,46].
Figure 3Phytochemicals with pancreatic-lipase-inhibitory properties [54,58].
Figure 4Phytochemical compounds acting by brown adipose tissue activation [73,74].